DENALI THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.31 USD | -2.21% |
|
+0.25% | -4.80% |
Financials (USD)
| Sales 2024 * | 45.66M | Sales 2025 * | 107M | Capitalization | 2.96B |
|---|---|---|---|---|---|
| Net income 2024 * | -426M | Net income 2025 * | -464M | EV / Sales 2024 * | 37.4 x |
| Net cash position 2024 * | 1.25B | Net cash position 2025 * | 1.05B | EV / Sales 2025 * | 17.9 x |
| P/E ratio 2024 * |
-7.57
x | P/E ratio 2025 * |
-7.59
x | Employees | 375 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -2.42% | ||
| 1 week | +11.91% | ||
| Current month | +11.91% | ||
| 1 month | +11.25% | ||
| 3 months | -0.76% | ||
| 6 months | +13.06% | ||
| Current year | -3.22% |
1 week
20.16
22.04
1 month
17.9322.04
Current year
14.5623.52
1 year
14.5633.31
3 years
14.5679.70
5 years
12.3993.94
10 years
12.3293.94
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | 0.00% | - | |
| 0.31% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 20.42 | -1.66% | 471 044 |
| 24-06-07 | 20.77 | -2.53% | 792,584 |
| 24-06-06 | 21.31 | -2.47% | 988,611 |
| 24-06-05 | 21.85 | +5.71% | 1,345,808 |
| 24-06-04 | 20.67 | +1.42% | 1,290,876 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-06-09
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
20.77
USD
Average target price
38.67
USD
Spread / Average Target
+86.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.22% | 2.96B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +2.15% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- DNLI Stock
